Post COVID-19 condition imposes significant burden in patients with advanced chronic kidney disease : A nested case-control study
Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved..
BACKGROUND: The burden of post COVID-19 condition (PCC) is not well studied in patients with advanced kidney disease.
METHODS: A large prospective cohort of SARS-CoV-2 vaccinated patients with chronic kidney disease stages G4-G5 (CKD G4/5), on dialysis, and kidney transplant recipients (KTR) were included. Antibody levels were determined after vaccination. Presence of long-lasting symptoms was assessed in patients with and without prior COVID-19 and compared using logistic regression. In patients with prior COVID-19, PCC was defined according to the WHO definition.
RESULTS: Two hundred sixteen CKD G4/5 patients, 375 dialysis patients, and 2005 KTR were included. Long-lasting symptoms were reported in 204/853 (24%) patients with prior COVID-19 and in 297/1743 (17%) patients without prior COVID-19 (aOR: 1.45 (1.17-1.78)], P < 0.001). PCC was prevalent in 29% of CKD G4/5 patients, 21% of dialysis patients, and 24% of KTR. In addition, 69% of patients with PCC reported (very) high symptom burden. Odds of PCC was lower per 10-fold increase in antibody level after vaccination (aOR 0.82 [0.70-0.96], P = 0.01) and higher in case of COVID-19 related hospital admission (aOR 4.64 [2.61-8.25], P = 0.003).
CONCLUSIONS: CKD G4/5 patients, dialysis patients, and KTR are at risk for PCC with high symptom burden after SARS-CoV-2 vaccination, especially if antibody levels are low and in case of hospitalization due to COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:142 |
|---|---|
| Enthalten in: |
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 142(2024) vom: 26. Apr., Seite 106990 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bouwmans, Pim [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 Vaccines |
|---|
| Anmerkungen: |
Date Completed 16.04.2024 Date Revised 16.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijid.2024.106990 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369183622 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369183622 | ||
| 003 | DE-627 | ||
| 005 | 20240416232622.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240302s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2024.106990 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1377.xml |
| 035 | |a (DE-627)NLM369183622 | ||
| 035 | |a (NLM)38428480 | ||
| 035 | |a (PII)S1201-9712(24)00061-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bouwmans, Pim |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Post COVID-19 condition imposes significant burden in patients with advanced chronic kidney disease |b A nested case-control study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.04.2024 | ||
| 500 | |a Date Revised 16.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND: The burden of post COVID-19 condition (PCC) is not well studied in patients with advanced kidney disease | ||
| 520 | |a METHODS: A large prospective cohort of SARS-CoV-2 vaccinated patients with chronic kidney disease stages G4-G5 (CKD G4/5), on dialysis, and kidney transplant recipients (KTR) were included. Antibody levels were determined after vaccination. Presence of long-lasting symptoms was assessed in patients with and without prior COVID-19 and compared using logistic regression. In patients with prior COVID-19, PCC was defined according to the WHO definition | ||
| 520 | |a RESULTS: Two hundred sixteen CKD G4/5 patients, 375 dialysis patients, and 2005 KTR were included. Long-lasting symptoms were reported in 204/853 (24%) patients with prior COVID-19 and in 297/1743 (17%) patients without prior COVID-19 (aOR: 1.45 (1.17-1.78)], P < 0.001). PCC was prevalent in 29% of CKD G4/5 patients, 21% of dialysis patients, and 24% of KTR. In addition, 69% of patients with PCC reported (very) high symptom burden. Odds of PCC was lower per 10-fold increase in antibody level after vaccination (aOR 0.82 [0.70-0.96], P = 0.01) and higher in case of COVID-19 related hospital admission (aOR 4.64 [2.61-8.25], P = 0.003) | ||
| 520 | |a CONCLUSIONS: CKD G4/5 patients, dialysis patients, and KTR are at risk for PCC with high symptom burden after SARS-CoV-2 vaccination, especially if antibody levels are low and in case of hospitalization due to COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chronic kidney disease | |
| 650 | 4 | |a Dialysis | |
| 650 | 4 | |a Kidney transplant recipient | |
| 650 | 4 | |a Long-COVID | |
| 650 | 4 | |a Post COVID-19 condition | |
| 650 | 4 | |a Solid organ transplant recipient | |
| 650 | 4 | |a immunocompromised | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Malahe, S Reshwan K |e verfasserin |4 aut | |
| 700 | 1 | |a Messchendorp, A Lianne |e verfasserin |4 aut | |
| 700 | 1 | |a Vart, Priya |e verfasserin |4 aut | |
| 700 | 1 | |a Imhof, Céline |e verfasserin |4 aut | |
| 700 | 1 | |a Sanders, Jan-Stephan F |e verfasserin |4 aut | |
| 700 | 1 | |a Gansevoort, Ron T |e verfasserin |4 aut | |
| 700 | 1 | |a de Vries, Aiko P J |e verfasserin |4 aut | |
| 700 | 1 | |a Abrahams, Alferso C |e verfasserin |4 aut | |
| 700 | 1 | |a Bemelman, Frederike J |e verfasserin |4 aut | |
| 700 | 1 | |a Vervoort, Johanna P M |e verfasserin |4 aut | |
| 700 | 1 | |a Hilbrands, Luuk B |e verfasserin |4 aut | |
| 700 | 1 | |a Ten Dam, Marc A G J |e verfasserin |4 aut | |
| 700 | 1 | |a van den Dorpel, René M A |e verfasserin |4 aut | |
| 700 | 1 | |a Rispens, Theo |e verfasserin |4 aut | |
| 700 | 1 | |a Steenhuis, Maurice |e verfasserin |4 aut | |
| 700 | 1 | |a Reinders, Marlies E J |e verfasserin |4 aut | |
| 700 | 1 | |a Hemmelder, Marc H |e verfasserin |4 aut | |
| 700 | 0 | |a RECOVAC Consortium |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases |d 1998 |g 142(2024) vom: 26. Apr., Seite 106990 |w (DE-627)NLM094730857 |x 1878-3511 |7 nnns |
| 773 | 1 | 8 | |g volume:142 |g year:2024 |g day:26 |g month:04 |g pages:106990 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijid.2024.106990 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 142 |j 2024 |b 26 |c 04 |h 106990 | ||